This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ohtani, K.-I. Articles by Mori, M. Search for Related Content PubMed PubMed Citation Articles by Ohtani, K.-I. Articles by Mori, M.

Troglitazone (CS-045) Inhibits ß-Cell Proliferation Rate Following Stimulation of Insulin Secretion in HIT-T 15 Cells

The First Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan

Address all correspondence and requests for reprints to: Dr. Ken-Ichi Ohtani, M.D., First Department of Internal Medicine, Gunma University School of Medicine, 3–39-22 Showa-machi, Maebashi Gunma 371, Japan. E-mail: kohtani{at}sb.gunma-u.ac.jp

Thiazolidinedione analogs are new antidiabetic agents that attenuate peripheral insulin resistance in noninsulin-dependent diabetic patients; however, the effects of these agents on insulin secretion are not known. We determined the short-term and long-term effects of troglitazone (CS-045) on insulin secretion in a Syrian hamster clonal ß-cell line, HIT-T 15 cells. The direct effect of troglitazone (CS-045: 10^-6–10^-4 M) on insulin secretion was examined in F-12 K incubation medium containing 7 mM glucose. CS-045 significantly stimulated insulin secretion within 10 min at the concentration of 10^-4 M and dose dependently stimulated insulin secretion within 60 min at the concentration of 10^-6–10^-4 M. The addition of 10^-5 M CS-045 showed an immediate increase of cytoplasmic free Ca²⁺ concentrations ([Ca²⁺]_i). Removal of extracellular Ca²⁺ by the addition of 1.5 mM EGTA completely abolished the 10^-4 M CS-045-induced insulin secretion for 10-min. Long-term incubation (24 h) with 10^-4 M CS-045 significantly decreased ß-cell insulin content and inhibited insulin secretion. During a 5-day incubation, CS-045 showed a dose-dependent reduction of insulin secretion measured during the final 24 h. Long-term incubation with CS-045 over 3 days inhibited the ß-cell proliferation rate, assessed with [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (MTT) assay. CS-045 dose dependently increased the amount of DNA fragmentation measured by ELISA. The addition of nifedipine failed to attenuate the reduction of ß-cell proliferation rate and insulin secretion by CS-045, nifedipine antagonized an increase in the amount of DNA fragmentation caused by 10^-4 M CS-045. The present studies provide evidence that CS-045 inhibits ß-cell function following an acute stimulation of insulin secretion in HIT-T 15 cells. The immediate stimulation of insulin secretion by CS-045 may be mediated by an increase in Ca²⁺ influx from extracellular space. The induction of apoptosis may partially involves the reduction of ß-cell number by CS-045.

This article has been cited by other articles:

				D. Gupta, T. L. Jetton, R. M. Mortensen, S. Z. Duan, M. Peshavaria, and J. L. Leahy In Vivo and in Vitro Studies of a Functional Peroxisome Proliferator-activated Receptor {gamma} Response Element in the Mouse pdx-1 Promoter J. Biol. Chem., November 21, 2008; 283(47): 32462 - 32470. [Abstract] [Full Text] [PDF]

				J. A. Moibi, D. Gupta, T. L. Jetton, M. Peshavaria, R. Desai, and J. L. Leahy Peroxisome Proliferator-Activated Receptor-{gamma} Regulates Expression of PDX-1 and NKX6.1 in INS-1 Cells Diabetes, January 1, 2007; 56(1): 88 - 95. [Abstract] [Full Text] [PDF]

				M. J. Luther, E. Davies, D. Muller, M. Harrison, A. J. Bone, S. J. Persaud, and P. M. Jones Cell-to-cell contact influences proliferative marker expression and apoptosis in MIN6 cells grown in islet-like structures Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E502 - E509. [Abstract] [Full Text] [PDF]

				J.-C. Henquin Pathways in Beta-Cell Stimulus-Secretion Coupling as Targets for Therapeutic Insulin Secretagogues Diabetes, December 1, 2004; 53(suppl_3): S48 - S58. [Abstract] [Full Text] [PDF]

				E. Santini, P. Fallahi, S. M. Ferrari, A. Masoni, A. Antonelli, and E. Ferrannini Effect of PPAR-{gamma} Activation and Inhibition on Glucose-Stimulated Insulin Release in INS-1e Cells Diabetes, December 1, 2004; 53(suppl_3): S79 - S83. [Abstract] [Full Text] [PDF]

				E. Zeender, K. Maedler, D. Bosco, T. Berney, M. Y. Donath, and P. A. Halban Pioglitazone and Sodium Salicylate Protect Human {beta}-Cells against Apoptosis and Impaired Function Induced by Glucose and Interleukin-1{beta} J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5059 - 5066. [Abstract] [Full Text] [PDF]

				K. Shimomura, H. Shimizu, M. Ikeda, S. Okada, M. Kakei, S. Matsumoto, and M. Mori Fenofibrate, Troglitazone, and 15-Deoxy-{Delta}12,14-prostaglandin J2 Close KATP Channels and Induce Insulin Secretion J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1273 - 1280. [Abstract] [Full Text] [PDF]

				K. Yajima, H. Hirose, H. Fujita, Y. Seto, H. Fujita, K. Ukeda, K. Miyashita, T. Kawai, Y. Yamamoto, T. Ogawa, et al. Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E966 - E971. [Abstract] [Full Text] [PDF]

				M.-A. Bae and B. J. Song Critical Role of c-Jun N-Terminal Protein Kinase Activation in Troglitazone-Induced Apoptosis of Human HepG2 Hepatoma Cells Mol. Pharmacol., February 1, 2003; 63(2): 401 - 408. [Abstract] [Full Text] [PDF]

				D. T. Finegood, M. D. McArthur, D. Kojwang, M. J. Thomas, B. G. Topp, T. Leonard, and R. E. Buckingham {beta}-Cell Mass Dynamics in Zucker Diabetic Fatty Rats: Rosiglitazone Prevents the Rise in Net Cell Death Diabetes, May 1, 2001; 50(5): 1021 - 1029. [Abstract] [Full Text]